SCHEMBL20969727

SCHEMBL20969727

COc1cc(F)c(CCN(c2nc3cccc(F)c3s2)C(C)c2ccc(C(=O)O)cc2)cc1F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 5/20 0.35
KARS1 Q15046 1/20 0.34
LMNA P02545 3/20 0.34
HTT P42858 2/20 0.34
MAPK1 P28482 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 4/20 0.33
RAD52 P43351 3/20 0.33
MEN1 O00255 3/20 0.33
PTGER4 P35408 2/20 0.33
CTSA P10619 2/20 0.33
GABRA1 P14867 1/20 0.32
CSNK2A2 P19784 1/20 0.32
CSNK2A1 P68400 1/20 0.32
KDM4E B2RXH2 1/20 0.32
PHGDH O43175 1/20 0.31
MITF O75030 1/20 0.31
MAPT P10636 1/20 0.31
IDE P14735 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20969638 0.90 KMT2A (0.34) TRPM8KARS1LMNAHTTMAPK1
SCHEMBL20969684 0.89 TRPM8 (0.34) TRPM8KARS1LMNAHTTKMT2A
SCHEMBL20969668 0.89 PTGER4 (0.40) TRPM8KARS1LMNAHTTMAPK1
SCHEMBL20969611 0.89 MRGPRX4 (0.34) TRPM8KARS1LMNAHTTMAPK1
SCHEMBL20969612 0.88 TAAR1 (0.34) TRPM8KARS1LMNAHTTMAPK1
SCHEMBL20969708 0.87 TRPM8 (0.33) TRPM8KARS1LMNAHTTKMT2A
SCHEMBL20969556 0.86 TRPM8 (0.41) TRPM8KMT2AMEN1GABRA1
SCHEMBL20969661 0.85 TAS2R14 (0.39) TRPM8KARS1LMNAHTTKMT2A
SCHEMBL20969677 0.85 TRPM8 (0.37) TRPM8KARS1HTTKMT2AMEN1
SCHEMBL20969728 0.85 KARS1 (0.38) TRPM8KARS1KMT2AMEN1PTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3483149-B1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME YUHAN CORP (KR) 2021-01-13 EP claimed
US-10383859-B2 Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same YUHAN CORPORATION (KR) 2019-08-20 US claimed
US-20190142809-A1 Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same YUHAN CORPORATION (KR) 2019-05-16 US claimed
EP-3483149-A1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Yuhan Corporation (KR) 2019-05-15 EP claimed
EP-3483149-B1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME YUHAN CORP (KR) 2021-01-13 EP disclosed
US-10383859-B2 Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same YUHAN CORPORATION (KR) 2019-08-20 US disclosed
US-20190142809-A1 Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same YUHAN CORPORATION (KR) 2019-05-16 US disclosed
EP-3483149-A1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Yuhan Corporation (KR) 2019-05-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190142809-A1 Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same ILK, SBDS, BDKRB1 TRPM8 772/4885KARS1 6/4885LMNA 619/4885
US-10383859-B2 Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same ILK, SBDS, BDKRB1 TRPM8 772/4885KARS1 6/4885LMNA 619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.